Professional Documents
Culture Documents
3 76 250 None 96
CorMedix Inc. 2H10 Urine Catalytic Iron Test Start assay development and validation
745 Route 202-206, Ste 303 Thixotropic Gel Start preclinical studies
Bridgewater, NJ 08807
(908) 517-9486 Deferiprone Interim analysis – Phase II CIN study
www.cormedix.com
Neutrolin Commence application process for CE mark in EU
Neutrolin IDE Submission
This executive summary contains certain statements that constitute forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about
our beliefs and expectations regarding results of our clinical trials, development timelines for our product candidates and future events, are forward-looking statements. These statements are not guarantees of future
performance and involve risks, uncertainties and assumptions that are difficult to predict. Pharmaceutical development inherently involves significant risks and uncertainties, including the risks outlined under “Risk
Factors” and elsewhere in our prospectus filed with the Securities and Exchange Commission on March 26, 2010 pursuant to Rule 424(b). Our actual results may differ materially from our expectations due to these
risks and uncertainties, including our dependence on the success of our lead product candidates, and factors relating to regulatory approval, research and development, intellectual property protection, competition,
industry environment, ability to raise sufficient capital and other matters. Any forward-looking statements included in this executive summary are based on information available to us on the date of this executive
summary. Except for our ongoing obligations to disclose material information under the federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report
events or to report the occurrence of unanticipated events.